Sekikawa Koji, Onogi Hitoshi, Yazawa Takashi, Sato Yu, Sakamoto Wataru, Miyamoto Kotaro, Fujita Shotaro, Suzuki Satoshi, Endo Yoshiyuki, Ohki Shinji, Takenoshita Seiichi
Dept. of Surgery II, Fukushima Medical University.
Gan To Kagaku Ryoho. 2006 Sep;33(9):1253-6.
The prognosis of patients with advanced esophageal cancer is still poor. Recently, concurrent chemoradiation therapy for esophageal cancer is being utilized with increasing frequency. In this study, we reported concurrent chemoradiation for patients with T4 esophageal cancer. From July 2000, we treated 21 consecutive patients with radiation and concurrent chemotherapy using intermittent low-dose FP chemoradiation (40 Gy radiation, 2 Gy/day, for 4 weeks 280/m(2) 5-FU intermittent 24 continuous, CDDP 8 mg/m(2)/intermittent). All patients who underwent the treatment with concurrent CRT completed the planned chemoradiation. Out of 21 patients, 2 (9.5%) showed a complete response and 9 patients (42.8%) showed a partial response. The 5-year survival rate of the T4 patients with CRT was almost the same as for those who underwent surgery alone. Concurrent chemoradiation therapy for T4 esophageal cancer patients is feasible and seems to be a standard treatment for T4 esophageal cancer patients. The results indicated that CRT is an effective therapy for advanced esophageal cancer.
晚期食管癌患者的预后仍然很差。最近，食管癌同步放化疗的使用频率越来越高。在本研究中，我们报告了T4期食管癌患者的同步放化疗情况。自2000年7月起，我们连续治疗了21例患者，采用间歇性低剂量FP同步放化疗（放疗40 Gy，2 Gy/天，共4周，5-FU 280/m² 间歇性持续24天，顺铂8 mg/m²/间歇性）。所有接受同步放化疗的患者均完成了计划的放化疗。21例患者中，2例（9.5%）完全缓解，9例（42.8%）部分缓解。接受同步放化疗的T4期患者的5年生存率与单纯接受手术的患者几乎相同。T4期食管癌患者的同步放化疗是可行的，似乎是T4期食管癌患者的标准治疗方法。结果表明，同步放化疗是晚期食管癌的有效治疗方法。
